Association of Accessible Medicines
Trade Association
Based in DC
AI Overview
With $1.8M in lobbying spend across 31 quarterly filings, Association of Accessible Medicines is a significant lobbying presence. They deploy 32 individual lobbyists Their lobbying covers 7 issue areas. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $300K |
| 2019 | $120K |
| 2020 | $220K |
| 2021 | $220K |
| 2022 | $180K |
| 2023 | $200K |
| 2024 | $300K |
| 2025 | $240K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Copyright/Patent, Pharmacy, Medicare/Medicaid, Budget/Appropriations, Trade and 2 more
Issues related to the use of sovereign immunity for patent protection.
S. 974 - Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act).
H.R. 2051 - Fair Access for Safe and Timely Generics Act of 2017 (FAST Generics Act of 2017).
S. 1348 - Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 (SPIKE Act).
Medicare Part D biosimilars; Medicaid generic rebate penalty.
H.R. 1892 - Bipartisan Budget Act of 2018, Omnibus.
Medicare Part D biosimilars; Medicaid generic rebate penalty.
Generic prescription drug issues.
H.R. 1892 - Bipartisan Budget Act of 2018, Omnibus.
Monitoring trade/tariff issues.
S. 974 - Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act).
H.R. 2051 - Fair Access for Safe and Timely Generics Act of 2017 (FAST Generics Act of 2017).
S. 1348 - Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 (SPIKE Act).
Medicare Part D biosimilars; Medicaid generic rebate penalty.
Generic prescription drug issues.
Showing 8 of 20 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.